PlainRecalls
FDA Devices Critical Class I Ongoing

Valiant Navion Thoracic Stent Graft System. For endovascular repair of lesions in the descending thoracic aorta (DTA).

Reported: March 17, 2021 Initiated: February 12, 2021 #Z-1201-2021

Product Description

Valiant Navion Thoracic Stent Graft System. For endovascular repair of lesions in the descending thoracic aorta (DTA).

Reason for Recall

Due to the presence of type IIIb endoleaks, stent fractures, and stent ring enlargement.

Details

Recalling Firm
Medtronic Vascular, Inc.
Units Affected
33,430 units
Distribution
Worldwide distribution. US Nationwide, Italy, Denmark, Germany, Finland, Chile, Russian Federation, Norway, South Africa, New Zealand, Australia, United Kingdom, Switzerland, Austria, Netherlands, Spain, Portugal, France, Israel, Greece, Thailand, Ireland, Colombia, Canada, Hong Kong, Sweden, Belgium, Saudi Arabia, Malaysia, Singapore, Brazil, Macau, Luxembourg, Viet Nam, Taiwan, Croatia, Serbia, United Arab Emirates, Slovenia, Philippines, Poland, Japan, Costa Rica, Hungary, Korea, Slovakia, Malta, Bahrain, Kuwait, Qatar, Reunion, Honduras, Mauritius, India, Peru, El Salvador, Ukraine, Uruguay, Trinidad and Tobago.
Location
Santa Rosa, CA

Frequently Asked Questions

What product was recalled?
Valiant Navion Thoracic Stent Graft System. For endovascular repair of lesions in the descending thoracic aorta (DTA).. Recalled by Medtronic Vascular, Inc.. Units affected: 33,430 units.
Why was this product recalled?
Due to the presence of type IIIb endoleaks, stent fractures, and stent ring enlargement.
Which agency issued this recall?
This recall was issued by the FDA Devices on March 17, 2021. Severity: Critical. Recall number: Z-1201-2021.